valproic acid has been researched along with Leukemia, Myeloid in 21 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| " For patients with high-risk MDS, VPA may be combined with chemotherapy or demethylating drugs." | 2.71 | Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. ( Fox, F; Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Knipp, S; Kuendgen, A; Steidl, C; Strupp, C, 2005) |
| "Valproic acid (VPA) has been used as an anticonvulsant for decades." | 2.44 | Valproic acid for the treatment of myeloid malignancies. ( Gattermann, N; Kuendgen, A, 2007) |
| " We conclude that valproic acid+ATRA+theophylline combined with 6-mercaptopurin or hydroxyurea can be safe and effective in palliative treatment of human AML." | 1.36 | Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases. ( Bruserud, Ø; Fredly, H; Gjertsen, BT; Stapnes Bjørnsen, C, 2010) |
| "Valproic acid is an effective anti-epileptic medication often used for long-term control of seizure disorders that has been implicated in hematological toxicities, including rare reports of myelodysplasia and acute leukemia." | 1.35 | Translocation-positive acute myeloid leukemia associated with valproic acid therapy. ( Ben-Ezra, J; Massey, GV; Riley, RS; Russell, EC; Williams, DC, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 16 (76.19) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hauswald, S | 1 |
| Duque-Afonso, J | 1 |
| Wagner, MM | 1 |
| Schertl, FM | 1 |
| Lübbert, M | 1 |
| Peschel, C | 1 |
| Keller, U | 1 |
| Licht, T | 1 |
| Lu, X | 1 |
| Ohata, K | 1 |
| Kondo, Y | 1 |
| Espinoza, JL | 1 |
| Qi, Z | 1 |
| Nakao, S | 1 |
| Goodyear, O | 1 |
| Agathanggelou, A | 1 |
| Novitzky-Basso, I | 1 |
| Siddique, S | 1 |
| McSkeane, T | 1 |
| Ryan, G | 1 |
| Vyas, P | 1 |
| Cavenagh, J | 1 |
| Stankovic, T | 1 |
| Moss, P | 1 |
| Craddock, C | 2 |
| Fredly, H | 1 |
| Stapnes Bjørnsen, C | 1 |
| Gjertsen, BT | 1 |
| Bruserud, Ø | 1 |
| Nie, D | 1 |
| Huang, K | 1 |
| Yin, S | 1 |
| Li, Y | 1 |
| Xie, S | 1 |
| Ma, L | 1 |
| Wang, X | 1 |
| Wu, Y | 1 |
| Xiao, J | 1 |
| Tang, R | 1 |
| Faussat, AM | 1 |
| Majdak, P | 1 |
| Perrot, JY | 1 |
| Chaoui, D | 1 |
| Legrand, O | 1 |
| Marie, JP | 1 |
| Pilatrino, C | 1 |
| Cilloni, D | 1 |
| Messa, E | 1 |
| Morotti, A | 1 |
| Giugliano, E | 1 |
| Pautasso, M | 1 |
| Familiari, U | 1 |
| Cappia, S | 1 |
| Pelicci, PG | 1 |
| Lo Coco, F | 1 |
| Saglio, G | 1 |
| Guerrasio, A | 1 |
| Bradbury, CA | 1 |
| Khanim, FL | 1 |
| Hayden, R | 1 |
| Bunce, CM | 1 |
| White, DA | 1 |
| Drayson, MT | 1 |
| Turner, BM | 1 |
| Kuendgen, A | 3 |
| Knipp, S | 2 |
| Fox, F | 1 |
| Strupp, C | 1 |
| Hildebrandt, B | 2 |
| Steidl, C | 2 |
| Germing, U | 2 |
| Haas, R | 2 |
| Gattermann, N | 3 |
| Schmid, M | 1 |
| Schlenk, R | 1 |
| Dohner, H | 1 |
| Ritter, M | 1 |
| Kattmann, D | 1 |
| Teichler, S | 1 |
| Hartmann, O | 1 |
| Samuelsson, MK | 1 |
| Burchert, A | 1 |
| Bach, JP | 1 |
| Kim, TD | 1 |
| Berwanger, B | 1 |
| Thiede, C | 1 |
| Jäger, R | 1 |
| Ehninger, G | 1 |
| Schäfer, H | 1 |
| Ueki, N | 1 |
| Hayman, MJ | 1 |
| Eilers, M | 1 |
| Neubauer, A | 1 |
| Blum, W | 1 |
| Marcucci, G | 1 |
| Deubzer, H | 1 |
| Busche, B | 1 |
| Rönndahl, G | 1 |
| Eikel, D | 1 |
| Michaelis, M | 1 |
| Cinatl, J | 1 |
| Schulze, S | 1 |
| Nau, H | 1 |
| Witt, O | 1 |
| Contini, P | 1 |
| Zocchi, MR | 1 |
| Pierri, I | 1 |
| Albarello, A | 1 |
| Poggi, A | 1 |
| Williams, DC | 1 |
| Massey, GV | 1 |
| Russell, EC | 1 |
| Riley, RS | 1 |
| Ben-Ezra, J | 1 |
| Cheng, YC | 1 |
| Lin, H | 1 |
| Huang, MJ | 1 |
| Chow, JM | 1 |
| Lin, S | 1 |
| Liu, HE | 1 |
| Bug, G | 1 |
| Schwarz, K | 1 |
| Schoch, C | 1 |
| Kampfmann, M | 1 |
| Henschler, R | 1 |
| Hoelzer, D | 1 |
| Ottmann, OG | 1 |
| Ruthardt, M | 1 |
| Smetana, K | 1 |
| Zápotocký, M | 1 |
| Starková, J | 1 |
| Trka, J | 1 |
| Mahlknecht, U | 1 |
| Schönbein, C | 1 |
| Aiken, TC | 1 |
| Collin, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma[NCT02761291] | Phase 1 | 18 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| Phase 0 Clinical Trial With Valproic Acid as a Chemopreventive Agent in Patients With Head and Neck Squamous Cell Carcinoma Previously Treated[NCT02608736] | Early Phase 1 | 42 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for valproic acid and Leukemia, Myeloid
| Article | Year |
|---|---|
Targeting epigenetic changes in acute myeloid leukemia.
Topics: Acetylation; Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Depsipeptide | 2005 |
Valproic acid for the treatment of myeloid malignancies.
Topics: Acute Disease; Apoptosis; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Histone Deace | 2007 |
3 trials available for valproic acid and Leukemia, Myeloid
| Article | Year |
|---|---|
Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Topics: Acute Disease; Aged; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes | 2005 |
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell | 2005 |
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemot | 2006 |
16 other studies available for valproic acid and Leukemia, Myeloid
| Article | Year |
|---|---|
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Biological Trans | 2009 |
Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis.
Topics: Caffeine; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Synergism; Gene Expression Regulation, L | 2010 |
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Topics: Acute Disease; Aged; Aged, 80 and over; Amino Acid Sequence; Antigens, Neoplasm; Antineoplastic Comb | 2010 |
Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Hist | 2010 |
Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells.
Topics: Acute Disease; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Sur | 2012 |
Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1.
Topics: Acute Disease; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; | 2004 |
Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.
Topics: Acetylation; Acute Disease; Adult; Antigens, CD34; Butyrates; DNA Methylation; Enzyme Inhibitors; Ge | 2005 |
Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, | 2006 |
Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells.
Topics: Anticonvulsants; Antigens, CD34; Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Cel | 2006 |
In vivo apoptosis of CD8(+) lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand.
Topics: Acute Disease; Adult; Aged; CD8-Positive T-Lymphocytes; Enzyme Inhibitors; Fas Ligand Protein; Femal | 2007 |
Translocation-positive acute myeloid leukemia associated with valproic acid therapy.
Topics: Acute Disease; Anticonvulsants; Cell Differentiation; Cell Division; Child, Preschool; Chromosomes, | 2008 |
Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cell Line, | 2007 |
Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia.
Topics: Adult; Aged; Antigens, CD34; Cell Culture Techniques; Cell Differentiation; Cell Division; Cell Line | 2007 |
Effect of histone deacetylase inhibitors on the cell nucleus and nucleolus of leukemic myeloblasts in vitro - a cytochemical study.
Topics: Apoptosis; Cell Line, Tumor; Cell Nucleus; Histone Deacetylase Inhibitors; Histone Deacetylases; Hum | 2007 |
Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells.
Topics: Acute Disease; Bone Marrow Cells; Cell Adhesion; Cell Line, Tumor; Cell Movement; Down-Regulation; D | 2008 |
A possible anti-emetic role for sodium valproate in cytotoxic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Drug Resistance; Epilepsy; Humans; Leukemia, Myeloid; Male; Midd | 1995 |